Open AccessMitochondrial Genomics and CD4 T-Cell Count Recovery After Antiretroviral Therapy Initiation in AIDS Clinical Trials Group Study 384
Author(s) -
Benjamin J. Grady,
David C. Samuels,
Gregory K. Robbins,
Doug Selph,
Jeffrey A. Canter,
Richard B. Pollard,
David W. Haas,
Robert W. Shafer,
Spyros A. Kalams,
Deborah G. Murdock,
Marylyn D. Ritchie,
Todd Hulgan
Publication year - 2011
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e31822c688b
Subject(s) - mitochondrial dna , human mitochondrial dna haplogroup , odds ratio , haplogroup , biology , confidence interval , viral load , population , medicine , immunology , genetics , oncology , genotype , haplotype , human immunodeficiency virus (hiv) , gene , environmental health
Mitochondrial DNA (mtDNA) variation has been associated with time to progression to AIDS and adverse effects from antiretroviral therapy (ART). In this study, full mitochondrial DNA (mtDNA) sequence data from US-based adult participants in the AIDS Clinical Trials Group study 384 was used to assess associations between mtDNA variants and CD4 T-cell recovery with ART.